Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India.
Home-grown pharma major Lupin Ltd on Wednesday said it has entered into a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets, a novel gastrointestinal drug, in the Indian market.
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India, the company said in a regulatory filing.
The drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths -- 10 mg and 20 mg, it added.
Lupin President India Region Formulations Rajeev Sibal said Vonoprazan is a novel treatment option for acid peptic disorders.
The pact with Takeda is "a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients," he added.
In India, Vonoprazan is approved by the DCGI (Drugs Controller General of India) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment, Lupin said in the filing.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How long will it take to build Rs 6 crore corpus with Rs 6,000, Rs 10,000 or Rs 15,000 monthly investments?
Highest Senior Citizen FD Rates: Check what banks like SBI, BoB, Canara Bank, HDFC Bank, ICICI Bank are providing on 1-yr, 3-yr, 5yr term deposits
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
02:56 PM IST